Dr. Holmes Answers the Question: Who is the right WATCHMANTM Patient?
“Boston Scientific is thrilled to be the first company to offer this innovative, proven, and life-enhancing therapy to patients meeting the indication for use.”
-- Ken Stein, MD, Senior Vice President and Chief Medical Officer of Rhythm Management
New Data Release
Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation
A Patient-Level Meta-AnalysisView article